Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease

This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.

Inclusion Criteria:

• Female participants must have negative results for pregnancy test performed on a serum sample obtained at Screening
• Body Mass Index is 18.0 to 35.0 at Screening
• Meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable Alzheimer's disease (AD).
• Meets the NIA-AA core clinical criteria for Mild Cognitive Impairment due to AD

Exclusion Criteria:

• Use of any strong inhibitors of drug metabolizing enzymes within 30 days prior to study drug administration
• Consumption of alcohol within 24 hours prior to study drug administration
• Positive screen for non-prescribed drugs of abuse or alcohol
• The participant has clinically significant abnormal laboratory values at Screening as determined by the investigator
• History of a drug or alcohol abuse within 6 months prior to study drug administration
• Current diagnosis of major depression or other major psychiatric disorder